Research programme: anticancer therapeutics - AbbVie/Celera
Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott Laboratories; Celera Diagnostics
- Developer AbbVie; Celera Corporation
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer